Pharmaceuticals & Therapeutics

As Aspen Aerogels prepares its Q4 results, investors weigh a challenging 2025 against a booming aerogel market and future EV growth prospects.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

Aethlon Medical's upcoming Q3 report puts its finances under a microscope as investors weigh a tight cash runway against progress on its Hemopurifier device.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

With a key cancer drug awaiting FDA review and pivotal data imminent, Celcuity faces investors at a critical juncture. What will they be looking for?

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

Final Phase 1b data for Kodiak Sciences' KSI-101 suggests a potential breakthrough for macular edema, a condition lacking dedicated biologic therapies.

A new six-month injection for Central Precocious Puberty shows strong safety and efficacy, promising to ease the treatment burden for children and families.

Landmark legislation targets pharmacy benefit managers to end restrictive practices, promising better access for patients with complex diseases.

As the FDA embraces advanced Bayesian statistics, MedTech firm BioStem sees validation for its wound care research, promising faster innovation for patients.

A new analysis of malpractice claims reveals the top drivers of patient harm in cardiology, offering critical insights to save lives and protect careers.

A new class of compounds 'disarms' TB bacteria instead of killing it, a breakthrough that could help defeat drug resistance and treat the world's deadliest disease.

A retired anesthesiologist suffers a catastrophic brain injury during surgery. Now, her family is taking a major healthcare provider to trial for negligence.

As PHINIA preps for its NYSE Investor Day, it plans to prove its value by balancing legacy engine tech with bold investments in a lower-carbon future.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

Eli Lilly partners with China's Zonsen PepLib, betting on its novel peptide platforms to fuel the next wave of therapies in oncology and metabolism.

New multi-year data for Fabry and Pompe disease therapies from Amicus Therapeutics showcases sustained benefits, offering new hope for long-term patient outcomes.

A new report reveals a major shift in hospital spending, with tech and infrastructure costs now rising faster than drugs for the first time in a decade.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.